BEYOND AIR INC

Beyond Air Inc. posts 107% revenue jump to $7.7M in FY 2026, slashing R&D costs and turning to profit, with strong outlook for continued growth in nitric‑oxide respiratory therapeutics.

Beyond Air, Inc. explores nitric‑oxide therapies for respiratory disease but faces volatile stock and negative earnings—high‑risk but potentially breakthrough.

Beyond Air’s $32 M NeuroNOS sale sparks a 165 % stock spike, funding its respiratory focus while eyeing lucrative autism therapy—an enticing, volatile biotech play.

Beyond Air, Inc. is a medical device and biopharmaceutical company focused on developing nitric oxide formulations and delivery systems to transform the treatment landscape for respiratory conditions.

Beyond Air Inc. is a medical device and biopharmaceutical company pioneering the use of nitric oxide to revolutionize respiratory health care and improve patient outcomes.

Beyond Air Inc. is a struggling biopharmaceutical company facing significant financial challenges despite its innovative approach to treating respiratory diseases.

Beyond Air Inc. is a struggling biopharmaceutical company facing significant financial challenges despite its innovative approach to treating respiratory diseases.